SCICLONE PHARMACEUTICALS INC Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for the quarter ending 2015-09-30 was $7.56M, a 35.25% increase year-over-year.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for the quarter ending 2015-06-30 was $2.52M, a 58.23% decline year-over-year.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for the quarter ending 2015-03-31 was $2.74M, a 6.54% increase year-over-year.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for fiscal 2015 was $12.81M, a 47.50% decline from fiscal 2014.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for fiscal 2014 was $24.40M, a 94.90% increase from fiscal 2013.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for fiscal 2013 was $12.52M, a 49.59% decline from fiscal 2012.
- SCICLONE PHARMACEUTICALS INC payments for repurchase of common stock for fiscal 2012 was $24.84M, a 610.62% increase from fiscal 2011.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $12.81M 10-K · filed 2017-03-09 |
| 2015-09-30 | $7.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $23.03M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $21.06M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-03-31 | $2.74M 10-Q · filed 2016-05-10 | $24.57M derived: sum of 4 quarters · filed 2017-03-09 |
| 2014-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $24.40M 10-K · filed 2017-03-09 |
| 2014-09-30 | $5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $16.86M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $6.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $18.61M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | $2.57M 10-Q · filed 2015-05-11 | $12.59M derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $12.52M 10-K · filed 2016-03-11 |
| 2013-09-30 | $7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $16.21M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $18.44M derived: sum of 4 quarters · filed 2015-03-12 |
| 2013-03-31 | $2.50M 10-Q · filed 2014-05-12 | $26.22M derived: sum of 4 quarters · filed 2015-03-12 |
| 2012-12-31 | $6.37M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $24.84M 10-K · filed 2015-03-12 |
| 2012-09-30 | $9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | |
| 2012-06-30 | $7.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | |
| 2012-03-31 | $1.12M 10-Q · filed 2013-08-09 | |
| 2011-12-31 | $3.50M 10-K · filed 2014-03-17 |